Key result
Early use of anakinra represents a potential therapeutic approach for managing myocarditis in patients with adult-onset Still's disease.
Why the study?
Does early use of anakinra improve outcomes in adult-onset Still's disease myocarditis?
Does early use of anakinra improve outcomes in adult-onset Still's disease myocarditis?
This paper discusses the early use of anakinra in treating myocarditis associated with adult-onset Still's disease.
Answers are grounded in this paper and cite their sources.
May warrant early anakinra consideration in Still's myocarditis; leaves open confirmation in larger RCTs.
"Early use of anakinra in adult-onset Still's disease myocarditis." Scandinavian Journal of Rheumatology, 47(6), pp. 511–512
No takes yet. Share an insight, caveat, or question.
Piel-Julian et al. (2018) studied this question. Early use of anakinra represents a potential therapeutic approach for managing myocarditis in patients with adult-onset Still's disease.
Synapse has enriched 10 related papers. Consider them for comparative context: